2022-04-04

NJBIZ Conversations: Chris Beddard

Chris Beddard, Vice President, U.S. Marketing, Integrated Diagnostic Solutions at BD

Chris Beddard is the Vice President, U.S. Marketing, Integrated Diagnostic Solutions at BD.

In this interview with NJBIZ, she speaks about the BD Onclarity™ HPV Assay, an HPV test with extended genotyping that holds the promise of improved outcomes. As long as women use it.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

Contemporary OB/GYN
Cervical Cancer | News & Updates
Contemporary OB/GYN: Harris Poll study from BD reveals knowledge gap and inequity in HPV screening and cervical cancer
BD submits pre-market approval supplement to FDA to enable ThinPrep® Pap Test™ PreservCyt® Solution to be used with the BD Onclarity™ HPV Assay
Cervical Cancer | News & Updates
Press release: BD submits pre-market approval supplement to FDA to enable ThinPrep® Pap Test™ PreservCyt® Solution to be used with the BD Onclarity™ HPV Assay
BD Onclarity HPV Assay
Cervical Cancer | News & Updates
Press Release: BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test